CTOs on the Move

A X I S

www.axispt.com

 
A X I S is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.axispt.com
  • 544 San Antonio Rd
    Mountain View, CA USA 94040
  • Phone: 650.229.1100

Executives

Name Title Contact Details

Similar Companies

Jen Care

JenCare Senior Medical Centers are family-owned primary and specialty care practices committed to delivering superior healthcare to Medicare-eligible seniors. Our care model now serves tens of thousands of seniors all across the country. And we`ll continue to expand to offer more seniors access to the quality healthcare they deserve.

Offsite Care Resources

Offsite Care Resources is a Sebastopol, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Focused Pain Relief

Focused Pain Relief is a Victor, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seasons

Seasons Hospice & Palliative Care (SHPC) is a community-based organization with an ongoing mission to find creative solutions that add quality to end-of-life care. The caregivers at SHPC hold steadfast to the patient/family focus of hospice care. We recognize that individuals and families are the experts in their own care, and we continuously strive for excellence beyond accepted standards. We are born into a world of comfort, warmth and love, and it our belief that we should all leave this world in the same way. To further that goal, we work with communities to increase the awareness of hospice as part of the continuum of care.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.